Everest Medicines Limited (1952.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Everest Medicines Limited
Sector
Healthcare
Industry
Biotechnology
Employees
665
First IPO Date
October 09, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Yongqing Luo | Chief Executive Officer & Executive Director | 16,871 | 1970 |
| Yifang Wu | Executive Chairman of the Board | 10,514 | 1969 |
| Ying Woo | Chief Financial Officer, President & Executive Director | 17,234 | 1973 |
| Chonggang Xu | Chief Operations Officer | 0 | 1969 |
| King Hang Yeung | Joint Company Secretary | 0 | 1992 |
| Wei Yang | Chief Scientific Officer | 0 | 1970 |
| Xu Liang | Chief Product Officer | 0 | 1969 |
| Jason Brown | Chief Business Officer | 0 | 1973 |
| Wenjun Liu | Co-President & Chief Commercial Officer | 0 | 1990 |
| Yee Wa Lau | Joint Company Secretary | 0 | 1973 |
Description
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
